![](https://www.diabetesnews.com/wp-content/uploads/2021/03/cholesterol-5977170_640-150x150.jpg)
Tirzepatide, a newer diabetes drug, has been shown to reduce patient hemoglobin A1c levels, as well as lowering body weight and improving insulin sensitivity markers in patients with type 2 diabetes. Read more
Tirzepatide, a newer diabetes drug, has been shown to reduce patient hemoglobin A1c levels, as well as lowering body weight and improving insulin sensitivity markers in patients with type 2 diabetes. Read more